Cargando…
Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
BACKGROUND: Cough and sputum are troublesome symptoms in chronic obstructive pulmonary disease (COPD) and are associated with adverse outcomes. The efficacy of aclidinium bromide 400 µg twice daily in patients with stable COPD has been established in two phase III studies (ACCORD COPD I and ATTAIN)...
Autores principales: | McGarvey, Lorcan, Morice, Alyn H, Smith, Jaclyn A, Birring, Surinder S, Chuecos, Ferran, Seoane, Beatriz, Jarreta, Diana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174811/ https://www.ncbi.nlm.nih.gov/pubmed/28074135 http://dx.doi.org/10.1136/bmjresp-2016-000148 |
Ejemplares similares
-
The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study
por: Smith, Jaclyn A., et al.
Publicado: (2019) -
Aclidinium inhibits human lung fibroblast to myofibroblast transition
por: Milara, Javier, et al.
Publicado: (2011) -
Adjuncts for sputum clearance in COPD: clinical consensus versus actual use
por: Barker, Ruth, et al.
Publicado: (2017) -
Chronic cough: new insights and future prospects
por: Morice, Alyn, et al.
Publicado: (2021) -
Decreased capsaicin cough reflex sensitivity predicts hospitalisation due to COPD
por: Kanemitsu, Yoshihiro, et al.
Publicado: (2023)